Clinical Trial VICCTHN1379


A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB/IV) (SELECT-1)

Principal Investigator(s)

Leora Horn


  • Protocol No. VICCTHN1379
  • Open Date: 02/21/2014
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To assess the efficacy in terms of Progression Free Survival (PFS) of selumetinib in combination with docetaxel compared to placebo in combination with docetaxel.
  • Disease Sites: Lung
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Docetaxel; Docetaxel (Taxotere); G-CSF; Selumetinib
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01933932
  • Secondary Protocol No: D1532C00079



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.